NKGen Biotech to Present Updated Phase 1 Data on SNK02 NK Cell Therapy in Solid Tumors at 2024 Summit

NKGen Biotech, Inc., a clinical-stage biotechnology firm headquartered in Santa Ana, California, is set to unveil significant advancements in its allogeneic natural killer (NK) cell therapy at the upcoming 6th Annual Allogeneic Cell Therapies Summit in Boston. Dr. Paul Y. Song, the company's Chairman and CEO, will lead a presentation on June 12, 2024, detailing their innovative cryopreserved NK cell therapy platform and updated Phase 1 clinical results targeting solid tumors without the need for lymphodepletion.

The presentation, titled "Protecting Patients by Removing Need for Lymphodepletion to Better Preserve Immune Function," will provide insight into the commercial manufacturing processes and cryopreservation techniques for their blood-derived allogeneic NK cell therapy, known as SNK02. Dr. Song will discuss the promising Phase 1 data indicating the efficacy of SNK02 in treating patients with advanced refractory solid tumors and highlight a notable deviation from traditional treatment methods.

Traditionally, lymphodepletion—a process that involves depleting a patient’s lymphocytes to enhance the effectiveness of subsequent therapies—has been a prerequisite for NK cell therapies. However, NKGen's approach with SNK02 circumvents this step, potentially minimizing treatment-related toxicity, preserving immune function, and enhancing overall therapeutic efficacy. This is a significant innovation, as it suggests that patients can undergo NK cell therapy without compromising their immune systems, which is crucial for their recovery and long-term health.

Dr. Song will also shed light on an unexpected finding from the Phase 1 trial of SNK02, suggesting that its applications could extend beyond cancer treatment. This discovery opens new avenues for research and potential therapeutic uses, broadening the impact of NKGen’s pioneering work in the field of cell-based immunotherapies.

The detailed presentation is expected to be available on NKGen's website following the summit. Additionally, previously shared Phase 1 data on the effectiveness of SNK02 in treating advanced solid tumors can also be found on the company’s website.

SNK02 represents a novel approach in the realm of cell-based therapies. It is an allogeneic NK cell immunotherapeutic derived from donor cells and expanded ex vivo. NKGen Biotech is dedicated to advancing SNK02 for various cancer treatments, emphasizing the broader potential of NK cell therapies.

NKGen Biotech focuses on the development and commercialization of innovative autologous, allogeneic, and CAR-NK cell therapies. These therapies harness the body's natural defenses to combat cancer and other diseases, offering a promising frontier in medical science. The company’s ongoing research and clinical trials aim to provide more effective and less toxic treatment options for patients.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!